ntracranIal atherosclerotic stenosis (ICAS) is one of the most common causes of stroke worldwide and is highly prevalent in black, Asian, and Hispanic populations. 4, 11 The global stroke burden attributed to ICAS is expected to rise because these populations are increasing globally.
clusions refractory to modern mechanical thrombectomy procedures. It should be considered when performing endovascular therapy in patients with ELVO, especially when encountering resistance during mechanical thrombectomy in regions where ICAS is prevalent. 15, 20 Moreover, even if reperfusion is achieved by thrombectomy, immediate re-occlusion occurs frequently in this variant of acute stroke. 7, 9 The optimal treatment strategy for patients with ELVO due to underlying ICAS is unclear. Several case series have reported outcomes after treatment with an intraarterial glycoprotein IIb/IIIa inhibitor or intracranial angioplasty with or without stenting after failed mechanical thrombectomy. 2, 9, 15, 20 In addition, predictors of outcomes after endovascular stroke therapy in patients with ELVO due to severe ICAS have not been studied. Accordingly, this study aimed to compare treatment outcomes from intracranial angioplasty with or without stenting versus intraarterial infusion of a glycoprotein IIb/IIIa inhibitor in patients with ELVO due to severe ICAS and investigate prognostic factors for a good outcome after endovascular therapy.
Methods

Patients
Between January 2011 and December 2016, a total of 140 consecutive patients with ELVO attributable to underlying severe ICAS (≥ 70% stenosis defined by the Warfarin-Aspirin Symptomatic Intracranial Disease [WASID] criteria 17 ) underwent endovascular therapy at two comprehensive regional stroke centers (A and B). Clinical and radiological data from both centers were prospectively collected into a database and retrospectively analyzed. We prospectively collected the following data: demographic features, cerebrovascular risk factors, National Institutes of Health Stroke Scale (NIHSS) score on admission, stroke subtypes according to Trial of Org 10172 in acute stroke treatment (TOAST) classification, 1 use of intravenous (IV) thrombolysis, time to procedure, procedure time, time to reperfusion, reperfusion status, and 3-month modified Rankin scale (mRS) score. This study was approved by the institutional ethics committee at both centers. Written informed consent for endovascular therapy was obtained from a family member in all patients.
Endovascular Therapy
All patients underwent a nonenhanced cranial CT scan and multimodal MRI before endovascular therapy. The inclusion criteria for endovascular therapy were as follows: presentation within 8 hours of stroke onset for an anterior circulation stroke and within 12 hours for a posterior circulation stroke; baseline NIHSS score ≥ 4; no intracranial hemorrhage detected on the cranial CT or MRI; occlusions of the intracranial internal carotid artery (ICA), middle cerebral artery (MCA), or basilar artery detected using MR angiography and confirmed by subsequent catheter angiography; for anterior circulation stroke, infarct volume on diffusion-weighted imaging (DWI) or nonenhanced CT less than one-third of the MCA territory; for posterior circulation stroke, no bilateral diffuse pontine ischemia on DWI; and premorbid mRS score ≤ 3.
Both cerebral angiography and endovascular therapy were performed under local anesthesia in all patients. When the pretreatment diagnostic angiography showed an intracranial large-vessel occlusion, either stent-retriever or manual aspiration thrombectomy was performed as the first-line endovascular therapy at the discretion of the treating neurointerventionalist. The details of the techniques used for mechanical thrombectomy have been described previously. 8, 14, 18 When underlying severe ICAS of the target artery was revealed on the follow-up angiography after a mechanical thrombectomy, two different rescue treatment strategies were used at each stroke center: emergent angioplasty/stenting or intraarterial infusion of tirofiban, a glycoprotein IIb/IIIa inhibitor. ICAS was determined if the fixed stenosis remained unchanged or was aggravated 5-10 minutes after intraarterial injection of a vasodilator through the guide catheter. An angiographic stenotic lesion with an intimal flap or double lumen was considered to be dissection.
At center A, subsequent emergent intracranial angioplasty was performed in all patients (Fig. 1) . Subsequent intracranial stenting was performed after angioplasty at the discretion of the neurointerventionalist. The devices and techniques used for intracranial angioplasty and stenting have been described in detail elsewhere. 20 When instant re-occlusion due to acute thrombosis occurred in the treated artery on the follow-up angiography after angioplasty/stenting, a bolus of 40,000-100,000 IU of urokinase was infused through a microcatheter. Neither heparin nor glycoprotein IIb/IIIa inhibitor was administered either intravenously or intraarterially during the endovascular procedure at center A. Aspirin (160 mg) and clopidogrel (225 mg) were given via nasogastric tube immediately after the procedure.
At center B, intraarterial infusion of tirofiban was performed as a primary rescue approach in all patients (Fig.  2) . Typically, 0.5 mg of tirofiban diluted with 8 ml of normal saline was injected with an infusion pump at a rate of 1 ml/min through a microcatheter placed just proximal to the stenosis. The total dosage of tirofiban ranged from 0.5 to 1.0 mg. A flat-panel detector CT scan (XperCT, Allura Xper FD 20/20; Philips) was performed to exclude intracranial hemorrhage prior to intraarterial tirofiban infusion. Follow-up angiography was performed immediately after and then 10 minutes after completion of infusion. Secondary intracranial angioplasty with stenting was permitted in cases refractory to intraarterial tirofiban infusion, which was defined as no visual improvement in the diameter of the stenotic vessel or blood flow distal to stenosis on follow-up angiography.
Outcome Measures
The start of endovascular therapy was defined as the moment the needle punctured the common femoral artery. Time to procedure was defined as the interval between time of onset of symptoms and start of endovascular therapy. At both centers, all patients underwent nonenhanced CT scans immediately and 24 hours after endovascular therapy. Intracerebral hemorrhages were assessed on posttreatment CT scans and classified as hemorrhagic infarction or parenchymal hemorrhage based on the European Cooperative Acute Stroke Study (ECASS) criteria. 5 Symptomatic intracranial hemorrhage was defined as any intracranial hemorrhage that caused neurological deterioration, defined as a ≥ 4-point increase in the NIHSS score. Reperfusion status was assessed using the final angiogram according to the modified treatment in cerebral infarction (m-TICI) scale, 21 with successful reperfusion defined as an m-TICI grade of 2b or 3. Assessment of angiographic images was performed by the consensus of two neuroradiologists (S.K.K. and B.H.B.) who were blinded to the procedure. Neurological evaluation was performed by a stroke neurologist immediately after treatment and 24 hours and 3 months after treatment, when there were changes in clinical symptoms, and before the patient was discharged. 
FIG. 2.
Brain images from a 69-year-old woman with acute ischemic stroke. A: Initial catheter angiography shows the occlusion (arrow) in the terminal segment of the right ICA. B: Angiography obtained after manual aspiration thrombectomy with a Penumbra reperfusion catheter reveals a concentric severe underlying stenosis (arrow) at the occlusion site. C: Angiography after intraarterial infusion of 0.5 mg of tirofiban through a microcatheter over 10 minutes shows complete reperfusion in the right MCA territory and severe residual stenosis (arrow). This patient has an aplasia of the A 1 segment of the right anterior cerebral artery. using the mRS score during an outpatient visit 3 months after treatment. If patients were unable to attend the outpatient clinic, the assessment was made via telephone interviews. A good outcome was defined as an mRS score ≤ 2 or equal to the premorbid mRS score.
Statistical Analysis
Continuous variables are presented as medians and interquartile ranges (IQRs). Discrete variables are presented as counts (n) and percentages (%). The c 2 test or Fisher exact test was used for comparing categorical and binary variables, and the Mann-Whitney U-test was used for comparing continuous variables. First, the baseline characteristics and clinical outcomes of the patients from the two centers (A and B) were compared. Second, the relationship between each clinical and procedural characteristic and the 3-month functional outcome was determined. Third, the independent associations of the 3-month functional outcome with other clinical and radiological variables were determined using a multivariate logistic regression analysis. The variables tested in the logistic regression models were those with p values < 0.1 in the univariate analysis. All statistical analyses were performed with SPSS software (version 23.0, IBM SPSS). A p value < 0.05 was considered significant.
Results
The data from 140 patients (91 men and 49 women, median age 67 years, range 30-88 years) were analyzed (Table 1 ). Center A included 72 patients and center B included 68. During the study period, the proportion of ICAS among patients who received mechanical thrombectomy for ELVO was 14.2% (72/508) in center A and 15.2% (68/447) in center B. Underlying severe ICAS that was attributed to ELVO and acute ischemic symptoms was most frequently observed in the MCA (n = 87) followed by the basilar artery (n = 29) and the ICA (n = 24). In the entire cohort, 65.7% (92/140) of patients had hypertension, 42.9% (60/140) had a smoking history, 42.1% (59/140) had dyslipidemia, 31.4% (44/140) had diabetes mellitus, 17.9% (25/140) had a history of prior ischemic stroke or transient ischemic attack (TIA), 12.1% (17/140) had atrial fibrillation, 7.1% (10/140) had a history of previous coronary artery disease, and 2.9% (4/140) had congestive heart failure. The median NIHSS score on admission was 13. Intra- venous thrombolysis was performed prior to endovascular therapy in 39.3% (55/140) of the patients. Overall, successful reperfusion (m-TICI 2b or 3) was achieved in 95% (133/140) of patients and a good outcome (mRS score 0-2) in 60% (84/140). Parenchymal hemorrhage occurred in 2.9% (4/140) and subarachnoid hemorrhage in 5.7% (8/140). Symptomatic hemorrhage occurred in 1 patient. The mortality rate was 7.9% (11/140).
Comparisons of Baseline Characteristics and Outcomes Between Centers A and B
The results of the comparison of patients from center A versus center B are shown in Table 1 . There were no significant differences between the patients from the two centers in age, sex, cerebrovascular risk factors, occlusion sites, and the use of IV recombinant tissue plasminogen activator (rt-PA). The baseline NIHSS score was higher in center B patients than center A (11 vs 15, p < 0.001). The median time to procedure (240 vs 378.5 min, p < 0.001), procedure time (37.5 vs 53 min, p < 0.001), and time to reperfusion (275 vs 463 min, p < 0.001) were significantly longer in center B patients than in center A. Stent-retriever thrombectomy was exclusively used as the first-line mechanical thrombectomy in center A and manual aspiration thrombectomy was used predominantly in center B (80.9%, n = 55/68). Intracranial angioplasty/stenting was performed more frequently in center A than center B (100% vs 8.8%, p < 0.001). Of the 72 patients in center A, 46 (64%) underwent angioplasty with stenting and 26 were treated with angioplasty alone. All 6 patients in center B underwent angioplasty with stenting. Subarachnoid hemorrhage tended to occur more frequently in center A patients than center B (9.7% vs 1.5%, p = 0.063). There were no significant differences between the two centers in the rate of successful reperfusion, parenchymal hemorrhage, symptomatic hemorrhage, 3-month mRS score, and mortality rate. There was no vessel rupture or angiographic extravasation of contrast medium during procedures in either center. In center A, 4 patients (5.6%) received intraarterial urokinase infusion due to instant re-occlusion after emergent angioplasty/stenting. These 4 patients achieved successful revascularization on final angiograms. In center B, 6 patients (8.8%) received rescue angioplasty and stenting due to instant re-occlusion. Successful revascularization was achieved in 4 of these 6 patients.
Associations Between Clinical and Procedural Factors and Functional Outcome
The results of the comparison between the patients with a good outcome and those with a poor outcome are shown Multivariate logistic regression analysis, including variables with a p value < 0.1 in a univariate analysis (age, sex, baseline NIHSS, history of previous coronary artery disease, history of previous stroke/TIA, and history of smoking), revealed the only independent predictor of good functional outcome was a lack of history of previous stroke or TIA (odds ratio = 0.254, 95% confidence interval 0.094-0.689, p = 0.007).
Discussion
The main findings of the present study were: 1) modern endovascular therapy can achieve high rates of successful reperfusion, good functional outcome, and a low rate of mortality in patients with acute ischemic stroke attributable to underlying severe ICAS; 2) there were no differences in treatment outcomes between patients treated with emergent angioplasty/stenting versus intraarterial infusion of a glycoprotein IIb/IIIa inhibitor; and 3) a lack of a history of previous stroke or TIA was the only independent predictor of good functional outcome after endovascular therapy in this patient population.
Treatment Options for ELVO Due to ICAS
Although the effectiveness of endovascular therapy in patients with acute ischemic stroke due to ELVO has now been demonstrated in recent randomized controlled studies, most of these patients had embolic occlusions. The optimal treatment for ELVO with underlying ICAS remains to be elucidated and there have been very few studies conducted on this topic. 2, 9, 15, 20 Currently, there are two potential endovascular therapeutic options when encountering underlying ICAS during mechanical thrombectomy procedures in patients with ELVO: angioplasty with or without stenting, and intraarterial infusion of an antiplatelet drug.
The major components of clots formed by in situ thrombosis are platelets and fibrin.
12,13 Thus, local infusion of an antiplatelet drug, such as a glycoprotein IIb/ IIIa inhibitor at the occlusion site, may be a reasonable therapeutic option in such patients. Tirofiban is a shortacting glycoprotein IIb/IIIa inhibitor and competitively inhibits platelet aggregation mediated by fibrinogen. The intraarterial use of tirofiban during neurointerventional procedures is known to be effective and safe. 3, 10 The main disadvantage of this approach would be instant or early re-occlusion of the treated artery because the severe stenosis itself remains unsolved. 7, 9 Recent studies also suggested that emergent angioplasty with or without stenting can be a viable therapeutic option in patients with acute stroke secondary to underlying ICAS. Yoon et al. reported that emergent angioplasty/stenting was associated with a high rate of good outcome and a low rate of hemorrhagic complications in such patients. 20 Expected disadvantages of intracranial angioplasty/stenting in the setting of acute stroke include vessel injury and in-stent thrombosis. To our knowledge, this is the first study to compare these two therapeutic options in patients with acute stroke secondary to underlying ICAS. Our study demonstrates that both treatment approaches are equally safe and effective in the treatment of ELVO due to severe ICAS. In our study, overall successful reperfusion was achieved in 95% and good functional outcome in 60% of patients. There was one symptomatic hemorrhage and mortality was only 7.9% at 3 months. Based on the results of our study, we suggest that treating physicians may choose the therapeutic option they are familiar with, either intracranial angioplasty/ stenting or intraarterial infusion of a glycoprotein IIb/IIIa inhibitor, as an adjuvant strategy for treating patients with ELVO due to severe ICAS. If one of either of the methods failed to achieve effective reperfusion, the other can be used as a rescue approach. Further multicenter randomized controlled studies are still needed to establish the optimal treatment for ELVO secondary to severe ICAS. An alternative treatment option for ELVO with severe ICAS is just to perform a mechanical thrombectomy alone and best medical therapy following thrombectomy. It is unclear at this moment that any additional endovascular procedures are required after adequate reperfusion has been achieved by thrombectomy, even if there is an underlying stenosis. These patients have presumably had long-standing stenosis that has not been symptomatic until the time of the acute event. These patients could be placed on intensive medical therapy after thrombectomy, which would include antiplatelet medication.
Predictors of Outcomes in Patients With ELVO Due to ICAS
There have been no reports regarding predictors of outcome after endovascular therapy in patients with ELVO and severe ICAS. Our study suggests that patients with recurrent stroke due to severe ICAS are likely to have poor functional outcome if they are presenting with ELVO. In the present study, we identified a lack of a history of previous stroke or TIA as the only independent predictor of good outcome (odds ratio 0.254, p = 0.007) after endovascular therapy in patients with ELVO due to severe ICAS. The WASID trial suggested that patients with symptomatic ICAS ≥ 70% are at high risk of subsequent stroke, predominantly in the territory of the stenotic artery. 11 Thus, our results together with the WASID trial reemphasize that more meticulous management of vascular risk factors is needed to prevent secondary stroke in patients with firstever stroke and severe intracranial stenosis ≥ 70%.
Our study confirms that achieving effective, quality reperfusion is one of the most important determinants of functional outcomes and quality reperfusion is more important than time in patients with acute stroke undergoing endovascular therapy, even in this variant of acute stroke due to underlying severe ICAS. 16, 19 When comparing two centers in the present analysis, there was significant baseline imbalance in the initial NIHSS score, time to procedure, procedure time, and time to reperfusion between the two centers. However, there were no significant differences in the rates of 3-month good outcome and mortality. This was probably due to the high rate of successful reperfusion achieved in both centers (95.8% and 94.1%, respectively). Moreover, the safety parameters, including the rates of parenchymal hemorrhage and symptomatic hemorrhage, were not significantly different between centers.
Limitations of the Study
This study has several limitations, including its retrospective and noncontrolled study design. In addition, angiographic stenosis after mechanical thrombectomy might occur due to residual adherent clot, dissection, or vasospasm; these would be difficult to differentiate from an atherosclerotic stenosis. However, fragmented residual clots would migrate to distal branches and do not adhere to the vessel wall when antegrade blood flow is restored after mechanical thrombectomy. Arterial dissection could be easily differentiated by its characteristic angiographic appearance, such as an intimal flap or double lumen. We performed additional angiographic runs 5-10 minutes after intraarterial injection of a vasodilator to differentiate fixed stenosis from vasospasm. Finally, there were baseline differences between the patients from the two centers in terms of initial NIHSS score, time to procedure, procedure time, and time to reperfusion, which might affect the results of this study. However, as mentioned earlier, these differences emphasize the importance of successful reperfusion in achieving good functional outcome in this patient population.
Conclusions
This study is the largest study showing that modern endovascular therapy can achieve a high rate of successful reperfusion and good outcome as well as a low rate of complications and mortality in acute stroke patients with ELVO due to severe ICAS. Our study suggests that both intracranial angioplasty/stenting and intraarterial infusion of a glycoprotein IIb/IIIa inhibitor are effective and safe in the treatment of underlying severe ICAS in patients with acute ischemic stroke. Further multicenter randomized controlled studies are still needed to determine the optimal treatment strategy in such patients. This treatment strategy should also include thrombectomy alone and subsequent best medical therapy. In addition, we found that a previous history of stroke/TIA was associated with a poor functional outcome at 3 months after endovascular therapy in this patient population. Thus, more meticulous management of vascular risk factors is needed to prevent secondary stroke in patients with first-ever stroke and severe ICAS.
